These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 36693125)
1. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125 [TBL] [Abstract][Full Text] [Related]
2. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker. Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272 [TBL] [Abstract][Full Text] [Related]
3. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors. Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563 [TBL] [Abstract][Full Text] [Related]
4. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Ogitani Y; Abe Y; Iguchi T; Yamaguchi J; Terauchi T; Kitamura M; Goto K; Goto M; Oitate M; Yukinaga H; Yabe Y; Nakada T; Masuda T; Morita K; Agatsuma T Bioorg Med Chem Lett; 2016 Oct; 26(20):5069-5072. PubMed ID: 27599744 [TBL] [Abstract][Full Text] [Related]
5. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522 [TBL] [Abstract][Full Text] [Related]
6. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma. Shi J; Jiao T; Guo Q; Weng W; Ma L; Zhang Q; Wang L; Zhang J; Chen C; Huang Y; Wang M; Pan R; Tang Y; Hu W; Meng T; Liu SH; Guo J; Kong Y; Meng X Cancer Res; 2023 Nov; 83(22):3783-3795. PubMed ID: 37668527 [TBL] [Abstract][Full Text] [Related]
7. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates. Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728 [TBL] [Abstract][Full Text] [Related]
8. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. Kong C; Pu J; Zhao Q; Weng W; Ma L; Qian Y; Hu W; Meng X; Meng T Mol Cancer Ther; 2023 Oct; 22(10):1128-1143. PubMed ID: 37352387 [TBL] [Abstract][Full Text] [Related]
9. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116 [TBL] [Abstract][Full Text] [Related]
10. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Ferraro E; Drago JZ; Modi S Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530 [TBL] [Abstract][Full Text] [Related]
11. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974 [TBL] [Abstract][Full Text] [Related]
12. Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates. Schöffski P; Wang CC; Schöffski MP; Wozniak A Oncol Res Treat; 2024; 47(1-2):18-41. PubMed ID: 38016427 [TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress. Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707 [TBL] [Abstract][Full Text] [Related]
14. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314 [TBL] [Abstract][Full Text] [Related]
15. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. Haikala HM; Lopez T; Köhler J; Eser PO; Xu M; Zeng Q; Teceno TJ; Ngo K; Zhao Y; Ivanova EV; Bertram AA; Leeper BA; Chambers ES; Adeni AE; Taus LJ; Kuraguchi M; Kirschmeier PT; Yu C; Shiose Y; Kamai Y; Qiu Y; Paweletz CP; Gokhale PC; Jänne PA Cancer Res; 2022 Jan; 82(1):130-141. PubMed ID: 34548332 [TBL] [Abstract][Full Text] [Related]
16. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473 [TBL] [Abstract][Full Text] [Related]
17. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126 [TBL] [Abstract][Full Text] [Related]
18. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer. Duro-Sánchez S; Nadal-Serrano M; Lalinde-Gutiérrez M; Arenas EJ; Bernadó Morales C; Morancho B; Escorihuela M; Pérez-Ramos S; Escrivá-de-Romaní S; Gandullo-Sánchez L; Pandiella A; Esteve-Codina A; Rodilla V; Dijcks FA; Dokter WHA; Cortés J; Saura C; Arribas J Cancer Res; 2022 Dec; 82(24):4670-4679. PubMed ID: 36222720 [TBL] [Abstract][Full Text] [Related]
19. Novel antibody-drug conjugates based on DXd-ADC technology. Chen R; Ren Z; Bai L; Hu X; Chen Y; Ye Q; Hu Y; Shi J Bioorg Chem; 2024 Oct; 151():107697. PubMed ID: 39121594 [TBL] [Abstract][Full Text] [Related]